How do we identify and measure value for patients with rare diseases?

Authors: Annie Kennedy and Joff Masukawa. Rare diseases impact 1 in 10 Americans, and over 400 million people worldwide. The current development and FDA approval process can cost hundreds of millions of dollars – and take an average of 15 years – to develop one therapy. For the 30% of children diagnosed with a rare [...]

2020-07-29T16:39:16-06:00July 22nd, 2020|Blog|

Measuring Value: COVID-19 Forces a Reassessment

Authors: Patricia Deverka, Jennifer Bright, Louis Garrison, Samuel Nussbaum We have seen the COVID-19 pandemic decimate people’s lives, health care systems, and the global and US economy, with investments by the US government exceeding $4 trillion dollars and with unemployment approaching 20%. In recent days, numerous articles have speculated on the pricing for Gilead’s new [...]

2020-07-15T11:27:08-06:00May 20th, 2020|Blog|